Key Takeaways
- • CPZ trades at $14.02 as of April 22, 2026, down 0.43% on the day, with a year-to-date decline of 3.6% and 12-month decline of 5.4%, indicating sustained downward momentum.
- • Technical downgrade to "Sell Candidate" status effective April 22, 2026, with forecasts predicting a 9.49% decline over the next three months and an expected price range of $11.62–$12.81 by end of Q2 2026.
- • Forward dividend yield of 11.93% ($1.68 annualized) provides income support, with an ex-dividend date of April 14, 2026, though high yield reflects the declining stock price.
- • Market capitalization of $276.62 million with a trailing P/E ratio of 14.2x and diluted EPS of $0.99 (trailing twelve months), positioning CPZ at a relatively modest valuation multiple.
- • 52-week trading range of $13.13–$16.82 shows the stock currently near the lower end of its annual range, down 16.2% from its 52-week high, with limited analyst coverage and no current consensus price targets.
Summary
Calamos Long/Short Equity & Dynamic Income Term Trust (CPZ) presents a mixed technical and fundamental picture as of mid-April 2026. The closed-end fund is trading at $14.02, reflecting recent weakness with a year-to-date return of negative 3.6% and a 12-month return of negative 5.4%. The stock has traded in a range of $13.13 to $16.82 over the past year and currently sits 16.2% below its 52-week high, placing it near the lower end of its annual trading band.
Technical analysis suggests near-term caution. As of April 22, 2026, CPZ has been downgraded to "Sell Candidate" status due to weaker technical conditions. Quantitative forecasts indicate the stock may experience a 9.49% decline over the subsequent three-month period, with a 90% probability of trading between $11.62 and $12.81 by the end of Q2 2026. The stock is described as occupying the upper part of a wide, falling short-term trend, which technical analysts typically view as a potential selling opportunity for tactical traders betting on mean reversion. A break above the $14.15 resistance level would be required to signal a potential trend shift.
The fund's income characteristics partially offset valuation concerns. CPZ offers a forward dividend yield of 11.93% based on an annualized distribution of $1.68 per share, which may appeal to income-focused investors, though the elevated yield reflects the compressed stock price. The fund maintains a market capitalization of approximately $276.6 million with a trailing P/E ratio of 14.2x and trailing twelve-month diluted earnings per share of $0.99, suggesting a relatively modest valuation on an earnings basis.
Analyst coverage remains sparse, with no current consensus price targets or forward guidance available in recent quarters. This limited institutional attention, combined with the technical downgrade and negative momentum metrics, suggests that prospective investors should demand clarity on the fund's portfolio positioning, income sustainability, and whether the elevated yield is supported by underlying asset fundamentals or reflects distressed pricing.
Technical analysis suggests near-term caution. As of April 22, 2026, CPZ has been downgraded to "Sell Candidate" status due to weaker technical conditions. Quantitative forecasts indicate the stock may experience a 9.49% decline over the subsequent three-month period, with a 90% probability of trading between $11.62 and $12.81 by the end of Q2 2026. The stock is described as occupying the upper part of a wide, falling short-term trend, which technical analysts typically view as a potential selling opportunity for tactical traders betting on mean reversion. A break above the $14.15 resistance level would be required to signal a potential trend shift.
The fund's income characteristics partially offset valuation concerns. CPZ offers a forward dividend yield of 11.93% based on an annualized distribution of $1.68 per share, which may appeal to income-focused investors, though the elevated yield reflects the compressed stock price. The fund maintains a market capitalization of approximately $276.6 million with a trailing P/E ratio of 14.2x and trailing twelve-month diluted earnings per share of $0.99, suggesting a relatively modest valuation on an earnings basis.
Analyst coverage remains sparse, with no current consensus price targets or forward guidance available in recent quarters. This limited institutional attention, combined with the technical downgrade and negative momentum metrics, suggests that prospective investors should demand clarity on the fund's portfolio positioning, income sustainability, and whether the elevated yield is supported by underlying asset fundamentals or reflects distressed pricing.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.